BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

Group 1 - BriaCell Therapeutics Corp. announced a public offering of 5.367 million units priced at $5.59 per unit, aiming for gross proceeds of approximately $30 million [1] - Each unit consists of one common share and one warrant, with the warrant exercisable at $6.93 per share and expiring five years from issuance [1] - Following the announcement, the stock price dropped 54.12% to $5.01 [2] Group 2 - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL," expected to begin trading on January 14, 2026 [2] - The offering is anticipated to close on January 15, 2026 [2] - The company plans to use the net proceeds for working capital and general corporate purposes [3] Group 3 - BriaCell recently reported a sustained complete resolution of lung metastasis in a breast cancer patient treated with its Bria-OTS personalized immunotherapy, boosting stock prices to $12.10 [3] - Over 11 months, the treatment response was confirmed without treatment-limiting toxicities, enhancing confidence in the Bria-OTS platform [4] - The stock traded between $3.00 and $98.20 over the past year, closing at $10.92, up 43.12% prior to the offering announcement [4]